ABCL
AbCellera Biologics Inc.
There isn't enough reported data to score ABCL yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ABCL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
ABCL's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ABCL PE Valuation
ABCL has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ABCL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ABCL's losses to grow, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ABCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.48 | +$0.09 |
| Q2 2026 | -$0.54 | +$0.01 |
| Q1 2026 | -$0.48 | +$0.08 |
| Q4 2025 | -$0.49 | +$0.06 |
| Q3 2025 | -$0.57 | +$0.03 |
| Q2 2025 | -$0.55 | -$0.02 |
| Q1 2025 | -$0.56 | -$0.05 |
| Q4 2024 | -$0.55 | -$0.04 |
ABCL is still losing money, but less than at its worst: $0.48 per share over the past year, against $0.60 at its worst in late 2024.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ABCL on earnings quality, reporting a profit while its opponent remains loss making.
ABCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.6M | +19% |
| Q2 2026 | $4.1M | -76% |
| Q1 2026 | $8.3M | +96% |
| Q4 2025 | $44.9M | +788% |
| Q3 2025 | $9M | +38% |
| Q2 2025 | $17.1M | +133% |
| Q1 2025 | $4.2M | -57% |
| Q4 2024 | $5.1M | -45% |
ABCL's revenue is recovering but still below its 2022 peak: $11M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -501% | +351 points |
| Q2 2026 | -1550% | -1260 points |
| Q1 2026 | -692% | +788 points |
| Q4 2025 | -64% | +1377 points |
| Q3 2025 | -852% | +588 points |
| Q2 2025 | -290% | +986 points |
| Q1 2025 | -1480% | -928 points |
| Q4 2024 | -1441% | -721 points |
ABCL's operating margin was −501% last quarter, up 351 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ABCL on profitability, with a higher operating margin.
ABCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.3M | +$86.8M |
| Q2 2026 | $23.8M | +$69.6M |
| Q1 2026 | -$37.4M | -$15.2M |
| Q4 2025 | -$44.6M | -$21M |
| Q3 2025 | -$61.5M | -$14.1M |
| Q2 2025 | -$45.8M | +$4.3M |
| Q1 2025 | -$22.2M | +$43.7M |
| Q4 2024 | -$23.6M | +$10.4M |
ABCL has burned cash in most quarters: −$33M over the past year, against −$153M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ABCL on cash generation, producing positive trailing cash flow while its opponent burns cash.
ABCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +12.5M shares |
| 1 year | +6.4% | +19.2M shares |
| 3 years | +9.9% | +28.6M shares |
| 5 years | +14% | +39.1M shares |
| Available history | +34% | +80.3M shares |
ABCL has 318M diluted shares, up 6.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ABCL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ABCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -1.6x | Net Cash |
| Q3 2022 | -1.1x | Net Cash |
| Q2 2022 | -2.8x | Net Cash |
| Q1 2022 | -1.9x | Net Cash |
| Q4 2021 | -2.2x | Net Cash |
| Q4 2020 | -3.5x | Net Cash |
| Q3 2020 | -12.0x | Net Cash |
| Q2 2020 | -14.9x | Net Cash |
ABCL has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ABCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.4 | Neutral |
| Stochastic | 62.7 | Neutral |
ABCL's weekly RSI is 61 (neutral) and its Stochastic is 63 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ABCL PE vs Healthcare Sector
| Metric | ABCL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ABCL has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ABCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.3 | 5.5% below |
| 20 week MA | $10.3 | 12% above |
| 50 week MA | $6.63 | 75% above |
| 100 week MA | $5.07 | 129% above |
| 200 week MA | $5.06 | 130% above |
ABCL's trend is up, with a small recent dip: it's below only its 8-week average, and 130% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
ABCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $42.4 | -28% |
| 2021 | $42.4 | $14.9 | -65% |
| 2022 | $14.9 | $10.3 | -31% |
| 2023 | $10.3 | $5.71 | -45% |
| 2024 | $5.71 | $2.99 | -48% |
| 2025 | $2.99 | $3.58 | +20% |
| 2026 YTD | $3.58 | $11.6 | +225% |
ABCL has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.